(5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7-methoxy-8-hydroxy-4-methyl-5H-2,3-benzodiazepine | 697754-53-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7-methoxy-8-hydroxy-4-methyl-5H-2,3-benzodiazepine
• 英文别名: (R)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine；(5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7-methoxy-4-methyl-5H-2,3-benzodiazepin-8-ol
• CAS: 697754-53-3
• 化学式: C₂₁H₂₄N₂O₄
• 分子量: 368.433
• InChiKey: SHRHVSNRULCERG-AWEZNQCLSA-N

物化性质

• 沸点：
  493.1±45.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Phosphodiesterase inhibitors
  申请人：Bernard Philippe

  公开号：US20070161628A1

  公开（公告）日：2007-07-12

  The invention relates especially to novel stereospecific derivatives of 2,3-benzodiazepine type as inhibitors of phosphodiesterases, especially 2 and 4, and uses thereof in the therapeutic field, most particularly for preventing and treating pathologies involving a central and/or peripheral disorder. The compounds of the invention more particularly correspond to the general formulae (I) and (II):

  该发明特别涉及2,3-苯二氮䓬啶类的新立体特异性衍生物，作为磷酸二酯酶，特别是2和4的抑制剂，以及在治疗领域中的用途，尤其是用于预防和治疗涉及中枢和/或外周障碍的病理。该发明的化合物更特别地对应于一般式(I)和(II)：
• Method of increasing neutrophil production using 2,3-benzodiazepines
  申请人：Vela Pharmaceuticals, Inc.

  公开号：US20040138210A1

  公开（公告）日：2004-07-15

  Compounds according to formula I: 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 and n are as defined herein, are administered to increase neutrophil levels in mammals.

  根据以下公式I：1，其中R1、R2、R3、R4、R5和n的定义如本文所述，用于增加哺乳动物中的中性粒细胞水平。
• Treatment of inflammatory disorders with 2,3- benzodiazepines
  申请人：Vela Pharmaceuticals, Inc.

  公开号：US20040138209A1

  公开（公告）日：2004-07-15

  Compounds according to formula I: 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 and n are as defined herein, are administered for the treatment of inflammatory disorders, particularly inflammatory disorders mediated by LTB 4 ,

  根据公式I:1，其中R1、R2、R3、R4、R5和n的定义如本文所述，用于治疗炎症性疾病，特别是由LTB4介导的炎症性疾病。
• Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
  申请人：——

  公开号：US20040106602A1

  公开（公告）日：2004-06-03

  Compounds according to formula I: 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 and n are as defined herein, are administered for the treatment of inflammatory disorders mediated by LTB 4 ,

  根据公式I：1，其中R1、R2、R3、R4、R5和n如本文所定义，用于治疗由LTB4介导的炎症性疾病。
• Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
  申请人：——

  公开号：US20040106601A1

  公开（公告）日：2004-06-03

  Compounds according to formula I: 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 and n are as defined herein, are administered to increase neutrophil levels in mammels.

  根据公式I：1中定义的R1、R2、R3、R4、R5和n，这些化合物被用于增加哺乳动物中的中性粒细胞水平。